MDS 2022 | Current challenges in PSP management

Rodolfo Savica, MD, PhD, Mayo Clinic, Rochester, MN, describes diagnostic barriers in progressive supranuclear palsy (PSP). Early symptoms of PSP, such as mild dizziness and double vision, tend to be similar to Parkinson’s disease and when the disease progresses, treatment may be less efficacious. Identifying strategies to earlier diagnose the disease is, therefore, necessary to improve outcomes in patients. Advancements in biomarkers, cerebrospinal fluid (CSF) analysis, and imaging are necessary to delay disease progression. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.